Rapport Therapeutics’ IPO came with a concurrent private placement that boosted the biotech’s cash haul. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S.

The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News.

Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.

The post J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS appeared first on MedCity News.

Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.

The post Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug appeared first on MedCity News.

Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.

The post With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO appeared first on MedCity News.

Metagenomi finds novel gene-editing tools by mining microbial samples from around the world. Already partnered with Moderna and Ionis Pharmaceuticals, the company said its IPO cash will support ongoing preclinical research.

The post Moderna & Ionis-Partnered Biotech Lands $94M in IPO Cash for Gene-Editing R&D appeared first on MedCity News.

Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.

The post Neuro Biotech Alto Adds $128M in IPO Cash for Biomarker-Based Psych Drugs appeared first on MedCity News.

Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.

The post Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO appeared first on MedCity News.

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.

The post ArriVent’s Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window appeared first on MedCity News.

CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follows the report of interim efficacy data showing a 75% complete response rate.

The post With Phase 3 Studies Ongoing in Bladder Cancer, CG Oncology Plots Course for IPO appeared first on MedCity News.

The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.

The post Lexeo’s IPO Raises $100M for Gene Therapies That Treat the Heart, Protect the Brain appeared first on MedCity News.

Abivax pulled off stock market deals in the U.S. and Europe that infuse the biotech with capital to continue clinical development of a small molecule for inflammation that’s differentiated from biologic therapies. In other biotech IPO news, Cargo Therapeutics and Invea Therapeutics both filed paperwork to go public.

The post Abivax Adds $236M to Show Its Anti-Inflammatory Med Can Stand Apart in Crowded Field appeared first on MedCity News.

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.

The post RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials appeared first on MedCity News.

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.

The post 3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff appeared first on MedCity News.

Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.

The post Turnstone Bio Goes IPO to Fund Clinical Tests of New Kind of Cancer Cell Therapy appeared first on MedCity News.

Inflammation and immunology biotech Apogee Therapeutics and Sagimet Biosciences, a company developing a drug for the fatty liver disease NASH, are the latest biotech companies to join the public markets. Both companies upsized their IPOs, raising cash for clinical trials.

The post Two Biotechs Break the IPO Dry Spell, Raising $385M Combined appeared first on MedCity News.

Biotech IPOs continues to be almost non-existent, but Acelyrin wants to see if the public markets have an appetite for its lead drug candidate. The small protein drug could match up favorably against blockbuster biologics and it has reached pivotal testing in three inflammatory disorders.

The post Acelyrin Plans IPO to Fund Pivotal Tests of Drug That Could Rival AbbVie’s Humira appeared first on MedCity News.

Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.

The post Mineralys IPO Lands $192M for Blood Pressure Trials and Chance to Challenge AstraZeneca appeared first on MedCity News.

Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.

The post Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologics appeared first on MedCity News.

Eli Lilly’s stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage clinical trials. While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.

The post Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds appeared first on MedCity News.

Third Harmonic Bio’s stock market debut was the only biotech IPO that crossed the $100 million threshold in the third quarter as the slowdown in IPO activity showed little sign of changing. Small deals continue to represent most of the IPO activity.

The post Biotech IPO market slowdown continues as third quarter is weakest since 2011 appeared first on MedCity News.

Third Harmonic Bio’s IPO raised $183.3 million for clinical development of an inflammation drug licensed from Novartis. The biotech was able to find enough investor interest to increase the deal size, offering 1.9 million more shares than initially planned.

The post Third Harmonic’s $183M stock market debut stands out in a sea of stalled IPOs appeared first on MedCity News.

Summer weather is heating up but the market for IPOs remains cold. Bausch + Lomb’s successful return to the public markets in the second quarter proved to be an exception as the slowdown in IPO activity reached levels not seen in years.

The post Biotech IPO freeze continues as second quarter is slowest in more than a decade appeared first on MedCity News.

PepGen’s technology improves the delivery of a therapy to more tissue types and the clinical-stage biotech plans to use its IPO cash to continue developing its lead program for Duchenne muscular dystrophy. Meanwhile, eye products giant Bausch + Lomb returned to the public markets as a standalone company. Both the PepGen and Bausch + Lomb IPOs priced below their respective price ranges.

The post PepGen IPO nabs $108M for muscular dystrophy drug with potential edge over Sarepta med appeared first on MedCity News.

Takeda Pharmaceutical spinout HilleVax broke the biotech IPO drought with a $200 million stock market debut for clinical development of a norovirus vaccine. Two eye health companies marked the other IPO activity: Belite Bio went public while Bausch + Lomb set financial terms for what could become one of the biggest IPOs of the year.

The post HilleVax’s IPO hauls in $200M for clinical test of VLP norovirus vaccine from Takeda appeared first on MedCity News.

AN2 is developing an antibiotic based on boron chemistry that could offer advantages over carbon-based molecules. The biotech plans to advance its drug candidate, licensed from Pfizer, to a pivotal test in a rare and potentially fatal lung infection caused by mycobacteria.

The post AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test appeared first on MedCity News.

Two biotechs are braving the roiling financial markets to raise money for clinical trials. AN2 Therapeutics is preparing for a pivotal test of its boron-based drug candidate for a rare, chronic lung disease. Okyo Pharma also filed IPO paperwork as it looks to advance to the clinic with its dry eye disease drug.

The post With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market appeared first on MedCity News.

Clinical-stage Arcellx raised $123.8 million from its IPO, which the company will use to advance to a pivotal test for its lead program, a CAR T-cell therapy for multiple myeloma. Though Arcellx trails its large pharmaceutical rivals, the biotech contends its technology produces cell therapies with key advantages.

The post Arcellx’s IPO raises $124M to fuel chase of better CAR T-cell therapy for cancer appeared first on MedCity News.

It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new biotech companies. Here’s a look at the IPOs of Amylyx Pharmaceuticals, CinCor Pharma, and Vigil Neuroscience, which raised a combined $482 million to support work on drugs addressing neurodegenerative and cardiovascular disorders.

The post Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review appeared first on MedCity News.

The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022.

The post Cell therapy, AI drug discovery highlight 2021’s record year in biotech IPOs appeared first on MedCity News.

Vaxxinity, a clinical-stage biotech with vaccine technology that gets the body to produce therapeutic or protective antibodies, raised $78 million from an IPO that priced below the targeted price range. In addition to its lead Alzheimer’s disease program, Vaxxinity’s pipeline includes product candidates for Parkinson’s disease, migraine, and Covid-19.

The post With claims of potential Alzheimer’s edge, Vaxxinity squeaks out $78M IPO appeared first on MedCity News.